Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhino conjunctivitis

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 253-260

  Rønborg, Steen M ^a   Svendsen, Ulrik G ^b   Micheelsen, Jesper S ^c   Ytte, Lars ^d   Andreasen, Jakob N ^e   Ehlers, Lars ^f  

^a Pulmonology and Allergy Clinic of Copenhagen   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Private ENT practice   (Denmark)

^d General Practice   (Denmark)

^e ALK ABELLÓ   (Denmark)

^f AALBORG UNIVERSITY   (Denmark)

Author keywords

Allergic rhino conjunctivitis; Allergy immunotherapy tablet; Budget impact analysis; Grass pollen; Health economics; Subcutaneous immunotherapy

Indexed keywords

ALUTARD; GRASS POLLEN VACCINE;

ALLERGIC RHINOCONJUNCTIVITIS; ARTICLE; BUDGET; BUDGET IMPACT ANALYSIS; COST CONTROL; DRUG COST; ECONOMIC EVALUATION; GRASS ALLERGY IMMUNOTHERAPY; GRASS POLLEN; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; IMMUNOTHERAPY; MEDICAL FEE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RESPIRATORY TRACT ALLERGY; RHINOCONJUNCTIVITIS; SALARY; SENSITIVITY ANALYSIS; SUBCUTANEOUS IMMUNOTHERAPY; TREATMENT DURATION;

EID: 84866534119     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004;24:758-764.
2. Dahl R, Andersen P, Chivato T, Valovirta E, de Monchy J. National prevalence of respiratory allergic disorders. Respir Med. 2004;98:398-403.
3. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol. 2001;107:3-8.
4. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy. 2007;62 Suppl 85:9-16.
5. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007;28:3-9.
6. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007;120:381-387.
7. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy. 1993;71:121-126.
8. Sundberg R, Toren K, Hoglund D, Aberg N, Brisman J. Nasal symptoms are associated with school performance in adolescents. J Adolesc Health. 2007;40:581-583.
9. Bousquet J, Khaltaev N, Cruz AA, etal. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8-160.
10. Plaut M, Valentine MD. Clinical practice. Allergic rhinitis. N Engl J Med. 2005;353:1934-1944.
11. European Medicines Agency. Guideline on the clinical development on products for specific immunotherapy for the treatment of allergic diseases. 2008. CHMP/EWP/18504/2006.
12. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:319-325.
13. Durham SR, Walker SM, Varga EM, etal. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468-475.
14. Durham S, Emminger W, Kapp A., et al Disease-modifying effect of the SQ-standardised grass allergy immunotherapy tablet is sustained 2 years after treatment. Allergy. 2010;65:689-690.
15. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006;61:185-190.
16. Dahl R, Kapp A, Colombo G., et al Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;118:434-440.
17. Dahl R, Kapp A, Colombo G., et al Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol. 2008;121:512-518.
18. Frølund L, Durham SR, Calderon M., et al Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. Allergy. 2010;65:753-757.
19. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011;127:72-80.
20. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of Timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011;127:64-71.
21. Durham SR, Emminger W, Kapp A., et al Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125:131-138.
22. Calderon M, Andersen JS, Lawton S. Meta-analysis supports that the efficacy of grass allergy immunotherapy tablets is comparable to subcutaneous immunotherapy. Allergy. 2011;Suppl 94:652-653.
23. Mauskopf JA, Sullivan SD, Annemans L., et al Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health. 2007;10:336-347.
24. Danish Medicines and Health Authority. Erfaringer med sundhedsøkonomiske analyser i ansøgninger om generelt tilskud til lægemidler. 2004. [Danish Medicines and Health Authority. Experiences with health economic analyses in drug reimbursement applications. 2004.]. Available from: http://laegemiddelstyrelsen.dk/da/topics/statistik,-priser-og-tilskud/tilskud-til-medicin/generelle-tilskud/ansoegning/sundhedsoekonomiske-analyser/erfaringer-med-sundhedsoekonomiske-analy-aegemidler. Accessed July 15, 2012. Danish.
25. Danish Tax and Customs Administration. Skattesatser 2009-2012. [Tax rates 2009-2012.]. Available from: http://skat.dk/SKAT.aspx?oId=2035568&vId=0&prev=2010&tab=. Accessed July 15, 2012. Danish.
26. Statistics Denmark. Earnings. Available from: http://iisboy4.dst.dk/statbank5a/SelectTable/omrade0.asp?Subjectcode=17&PLanguage=1&Shownews=OFF&tree=false. Accessed July 15, 2012.
27. National Board of Health Denmark. Takstsystem 2010 Vejledning (DAGS fees). [System of charges 2010 instruction (DAGS fees).]. Available from: http://www.sst.dk/publ/Publ2010/SESE/Takst/Takstvejledning_%202010.pdf. Accessed July 15, 2012. Danish.
28. Danish Medical Association. §56 Ydelser i dagtiden (wage and fees). [§56 Day time payments (wage and fees).]. Available from: http://www.laeger.dk/portal/page/portal/LAEGERDK/Laegerdk/P_L_O/Overenskomster/Honorartabel/Honorartabel%201-204-12/%C2%A7%2056%20Ydelser%20i%20dagtiden1. Accessed July 15, 2012. Danish.
29. Danish Medicines and Health Authority. List of medicine prices. Available from: http://www.medicinpriser.dk/; url http://laegemiddelstyrelsen.dk/da/topics/statistik,-priser-og-tilskud/priser-paa-medicin/prisudvikling/priser-de-seneste-5-aar. Accessed July 15, 2012.
30. GINA Executive Committee. Global Initiative for Asthma; Global Strategy for Asthma Management and Prevention, 2009. Bethesda, MD: National Heart, Lung and Blood Institute, National Institute of Health; 2009.
31. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;12:CD002893.
32. Passalacqua G, Compalati E, Canonica GW. Sublingual immunotherapy for allergic rhinitis: an update. Curr Opin Otolaryngol Head Neck Surg. 2011;19:43-47.
33. Andreasen JN, Lawton S, Bæch SB, Svärd M. Compliance and persistence to grass immunotherapy treatment is comparable for allergy immunotherapy tablets and subcutaneous immunotherapy: a Swedish registry study. Abstract presented at World Allergy Congress, December 4-8, 2011, Cancun, Mexico.